Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live News

CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma, announced that it has obtained marketing authorisation from UK`s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version. Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins. Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer.Powered by Capital Market - Live News

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma,  announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has adopted a positive opinion for Zefylti (BP13, a filgrastim biosimilar) recommending the granting of a marketing authorisation. Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells (PBPCs). Commenting on the update the company spokesperson said, After receiving the GMP certificate of compliance from the European Medicines Agency (EMA) in November, Zefylti is our first biosimilar to receive a positive opinion from EMA`s CHMP. Two more products, our biosimilar versions of pegylated filgrastim (BP14) and trastuzumab (BP02), are currently under review with the EMA, and a biosimilar to bevacizumab (BP01) is under review with the MHRA. We are confident and on track to bring these treatment options to patients next year.Powered by Capital Market - Live News

Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. The product is expected to be launched in Q4FY25. The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA. This is the 179 th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. Pazopanib Tablets, 200 mg is indicated for the treatment of adults with Advanced Renal Cell Carcinoma (RCC), and Advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy.Powered by Capital Market - Live News

Aurobindo Pharma USA Inc., a wholly owned subsidiary of Aurobindo Pharma, has entered into a collaboration and license agreement on 22 November 2024 with a global pharma major for development of specific products across respiratory therapeutic area and their commercialisation.Powered by Capital Market - Live News